THE first treatment for patients
with a rare disease known as
lysosomal acid lipase (LAL)
deficiency, or Wolman disease and
cholesteryl ester storage disease,
has been approved by the US Food
and Drug Administration.
The new product is Kanuma
(sebelipase alfa) a once-weekly
intravenous therapy that provides
a protein that functions in place of
the missing or only partially active
LAL protein in the patient.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 15
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.